Stocks · News reference
ENvue Medical has transitioned the manufacturing of its UroShield therapeutic ultrasound device to the United States and initiated commercial shipments to its exclusive distributor for the UK and Ireland, Peak Medical.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
ENvue Medical, Inc. CEO Dr. Doron Besser issued a letter to shareholders outlining the company's strategic focus on achieving profitability, driving market adoption, and improving financial performance following its transition to the OTC market.
Filed: 2026-10-14 AccNo: 0001493152-26-047063 Size: 822 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
ENvue Medical shares fall after Nasdaq decision as FEED prepares to trade on OTC Markets.
ENvue Medical, Inc. (NASDAQ: FEED) announced that the Nasdaq Hearings Panel denied its request for continued listing on The Nasdaq Capital Market. The company's stock will be suspended from Nasdaq and begin trading on OTC Markets under the same symbol 'FEED' on September 16, 2026. Despite the delisting, ENvue stated that its business operations, products, and commercial activities remain unaffected, and the company is evaluating all available appeal options while continuing to focus on commercializing its medical technology portfolio.